Skip to content

Comparison of the effect of portulaca oleracea L. and foeniculum vulgare mill and vitex agnus castus L. with spironolactone and cyproterone compound on hirsutism on patient with polycystic ovary syndrome

Comparison of the effect of portulaca oleracea L. and foeniculum vulgare mill and vitex agnus castus L. with spironolactone and cyproterone compound on hirsutism on patient with polycystic ovary syndrome

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016062121653N7
Enrollment
128
Registered
2017-10-01
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: The herbal diet intervention group contains 6 capsules per 24 hours, each dose of each capsule is 550 mg, and each capsule contains 25% portulaca oleracea L.(137 mg) + 25% foeniculum
Treatment - Drugs
The herbal diet intervention group contains 6 capsules per 24 hours, each dose of each capsule is 550 mg, and each capsule contains 25% portulaca oleracea L.(137 mg) + 25% foeniculum vulgare mill (1
To the control group, the spironolactone (one daily dose of 100 mg) and cyproterone compound (one tablet daily dose of 50 mg) are given

Sponsors

Vice chancellor for research ,Jahrom University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: inclusion criteria :oral and written judgment for participation in the study; in the age range of 18 to 40 years of age ; absence of chronic physical illness (other than polycystic ovary syndrome), and mental illness or drug use In the long time, it has been the patient's own words. Exclusion criteria : history of specific drug use (effects on levels of hormones, blood glucose, insulin or hirsutism); previous history of diabetes, cardiovascular disease, thyroid disease ; other surgical and internal diseases. They do not have PCOS cryptography.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hirsutism. Timepoint: 3 month. Method of measurement: Ferriman-Gallway Scoring system.

Secondary

MeasureTime frame
Free testosterone. Timepoint: 3month. Method of measurement: mg/ml.;Follicle-stimulating hormone. Timepoint: 3 month. Method of measurement: mg/ml.;Luteinizing Hormone. Timepoint: 3 month. Method of measurement: mg/ml.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohadeseh Karimi

Jahrom University of Medical Sciences

mohadesehkarimi2318@gmail.com+98 71 5422 7658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026